Prediction of Human Pharmacokinetics of Panipenem-betamipron, a New Carbapenem, from Animal Data

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 Sep 1

PMID 1416872

Citations 7

Authors

A Kurihara

H Naganuma

M Hisaoka

H Tokiwa

Y Kawahara

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetic behavior of panipenem (PAPM)-betamipron (BP), a new carbapenem, in humans was successfully predicted from data collected from six animal species. PAPM and BP were biphasically eliminated from plasma after intravenous (i.v.) administration of PAPM-BP to mice, guinea pigs, rats, rabbits, monkeys, and dogs. Elimination rates of PAPM and BP were correlated with animal size: the larger the animal was, the slower the elimination was. As for PAPM and BP, log-log plots of total plasma clearance (CLtot) versus body weight and log-log plots of distribution volume at steady state (VSS) versus body weight for six animal species were linear, with high correlation coefficients. These allometric equations were extrapolated to predict CLtot and VSS for PAPM and BP in humans. In addition, concentration in plasma-time profiles for humans were predicted by using two-exponent equations fitted to the complex Dedrick plot of animal data. Predicted values for CLtot and VSS for PAPM and BP in humans agreed well with observed values in humans given 750/750 mg of PAPM-BP as an i.v. drip infusion for 30 min. Predicted concentration in plasma-time profiles for humans approximated observed profiles. Thus, the pharmacokinetics of PAPM-BP extrapolated well from animal species to humans when allometric equations and the complex Dedrick plot were used.

Citing Articles

Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Bamfo N, Hosey-Cojocari C, Benet L, Remsberg C Pharm Res. 2021; 38(7):1139-1156.

PMID: 34254223 PMC: 9855226. DOI: 10.1007/s11095-021-03076-y.

Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future.

Smith P, Zuccotto F, Bates R, Martinez-Martinez M, Read K, Peet C ACS Infect Dis. 2018; 4(10):1439-1447.

PMID: 30141902 PMC: 6189874. DOI: 10.1021/acsinfecdis.8b00160.

Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Huh Y, Smith D, Feng M Xenobiotica. 2011; 41(11):972-87.

PMID: 21892879 PMC: 4181675. DOI: 10.3109/00498254.2011.598582.

Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Hu T, Hayton W AAPS PharmSci. 2002; 3(4):E29.

PMID: 12049492 PMC: 2751218. DOI: 10.1208/ps030429.

Prediction of drug clearance in humans from laboratory animals based on body surface area.

Liu X, Chen J Eur J Drug Metab Pharmacokinet. 2002; 26(4):249-55.

PMID: 11808867 DOI: 10.1007/BF03226379.

References

Norrby S, ALESTIG K, Bjornegard B, Burman L, Ferber F, Huber J . Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983; 23(2):300-7. PMC: 186041. DOI: 10.1128/AAC.23.2.300. View

Boxenbaum H . Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984; 15(5-6):1071-121. DOI: 10.3109/03602538409033558. View

KROPP H, Sundelof J, Hajdu R, KAHAN F . Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982; 22(1):62-70. PMC: 183675. DOI: 10.1128/AAC.22.1.62. View

Yamaoka K, Tanigawara Y, Nakagawa T, Uno T . A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981; 4(11):879-85. DOI: 10.1248/bpb1978.4.879. View

Yamaoka K, Nakagawa T, Uno T . Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978; 6(6):547-58. DOI: 10.1007/BF01062109. View

Nakashima E, Yokogawa K, ICHIMURA F, Kurata K, Kido H, Yamaguchi N . A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans. Chem Pharm Bull (Tokyo). 1987; 35(2):718-25. DOI: 10.1248/cpb.35.718. View

Rowland M . Physiologic pharmacokinetic models and interanimal species scaling. Pharmacol Ther. 1985; 29(1):49-68. DOI: 10.1016/0163-7258(85)90016-6. View

Dedrick R . Animal scale-up. J Pharmacokinet Biopharm. 1973; 1(5):435-61. DOI: 10.1007/BF01059667. View

Boxenbaum H, Ronfeld R . Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol. 1983; 245(6):R768-75. DOI: 10.1152/ajpregu.1983.245.6.R768. View

10.

Boxenbaum H . Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982; 10(2):201-27. DOI: 10.1007/BF01062336. View

11.

Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M . Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobiodyn. 1990; 13(10):602-11. DOI: 10.1248/bpb1978.13.602. View

12.

Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K . Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. Cancer Chemother Pharmacol. 1990; 27(1):20-6. DOI: 10.1007/BF00689271. View

13.

McGovren J, Williams M, Stewart J . Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos. 1988; 16(1):18-22. View

14.

Mordenti J . Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986; 75(11):1028-40. DOI: 10.1002/jps.2600751104. View

15.

Mordenti J . Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob Agents Chemother. 1985; 27(6):887-91. PMC: 180180. DOI: 10.1128/AAC.27.6.887. View

16.

Swabb E, Bonner D . Prediction of aztreonam pharmacokinetics in humans based on data from animals. J Pharmacokinet Biopharm. 1983; 11(3):215-23. DOI: 10.1007/BF01061865. View